GOVX.US GeoVax Labs Inc

Healthcare Biotechnology USA Stocks
1.70 USD
Close of Nov 14, 2026
1.57 270.66
Market cap
USD 718K
P/E
-
P/B
0.48x
ROE
-1,608.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is GOVX.US undervalued?

Graham number

The Graham number of GeoVax Labs Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GeoVax Labs Inc fundamental analysis

No fundamental analysis for GeoVax Labs Inc yet.

GeoVax Labs Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GeoVax Labs Inc

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and…

Full company profile